Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

470.01 -4.28 (-0.90%)
Streaming Delayed Price Updated: 9:38 AM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Second Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Vertex to Announce Second Quarter 2023 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
MarketBeat Week in Review – 5/15 - 5/19
Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports First Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Records 52-Week High Thursday Morning
Via Investor Brand Network
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Sets New 52-Week High in Wednesday Session
Via Investor Brand Network
Vertex to Announce First Quarter 2023 Financial Results on May 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Small Financial Software Makers Showing Strong Chart Action
Financial software firms Intapp, Vertex, and GuidewIre are headed toward greater profitability and also boast strong chart action. 
Via MarketBeat
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
A recent announcement by Vertex Pharmaceuticals is confirming a technical signal that could allow the stock to make a new run at its 52-week high 
Via MarketBeat
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.